Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Squamous Cell Carcinoma Esophagus: Demographics and Evaluation of Prognostic Factors at a Tertiary Care Center in India

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Neoadjuvant chemoradiation followed by surgery has been the standard of care for locally advanced carcinoma esophagus. We present our experience and inference of various factors associated with the same treatment and the prognostic influence of the same. A retrospective analysis of a cohort of 132 squamous cell carcinoma esophagus patients post neoadjuvant chemoradiation operated with curative intent was carried out. The 2-year overall survival rate was 64.5%. A pathological complete response was achieved in 32.5% of patients and was the only factor that significantly determined overall survival (p = 0.048). Neoadjuvant chemoradiation before surgery for locally advanced squamous cell cancer of the esophagus remains the standard of care with a pathological complete response being a significant factor in predicting overall survival. More prospective randomized studies are necessary to analyze factors affecting and predicting a pathological complete response which would help organ preservation in patients with a complete response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References 

  1. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  2. [Internet]. Main.icmr.nic.in. 2022 [cited 14 February 2022]. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/Esophagus%20final%20ICMR2014_0.pdf

  3. Samarasam I (2017) Esophageal cancer in India: current status and future perspectives. Int J Adv Med Health Res 4(1):5

    Article  Google Scholar 

  4. Pandey V, Choksi D, Kolhe K, Ingle M, Rathi C, Khairnar H et al (2020) Esophageal carcinoma: an epidemiological analysis and study of the time trends over the last 20 years from a single center in India. J Fam Med Prim Care 9(3):1695

    Article  Google Scholar 

  5. Hur C, Miller M, Kong C, Dowling E, Nattinger K, Dunn M et al (2012) Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119(6):1149–1158

    Article  PubMed  Google Scholar 

  6. Mawhinney MR, Glasgow RE (2012) Current treatment options for the management of esophageal cancer [Internet]. U.S. National Library of Medicine. [cited 2023 Oct 5] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496368/

  7. van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, Henegouwen M, Wijnhoven B et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084

    Article  PubMed  Google Scholar 

  8. Gebski V, Burmeister B, Smithers B, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8(3):226–234

    Article  CAS  PubMed  Google Scholar 

  9. AJCC Cancer Staging Manual [Internet]. SpringerLink. 2022 [cited 14 August 2022]. Available from: https://link.springer.com/book/9783319406176

  10. Berger A, Farma J, Scott W, Freedman G, Weiner L, Cheng J et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23(19):4330–4337

    Article  PubMed  Google Scholar 

  11. Meredith K, Weber J, Turaga K, Siegel E, McLoughlin J, Hoffe S et al (2010) Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 17(4):1159–1167

    Article  PubMed  Google Scholar 

  12. Donahue J, Nichols F, Li Z, Schomas D, Allen M, Cassivi S et al (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2):392–399

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shi C, Berlin J, Branton PA et al (2017) In: available at http://www.cap.org (ed) Protocol for the examination of specimens from patients with carcinoma of the esophagus. College of American Pathologists Cancer Protocols, pp 1–17

    Google Scholar 

  14. Li S, Rau K, Lu H, Wang Y, Tien W, Liang J et al (2012) Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg 42(6):958–964

    Article  PubMed  Google Scholar 

  15. Wu Y, Li J (2021) Change in maximal esophageal wall thickness provides prediction of survival and recurrence in patients with esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and surgery. Cancer Manag Res 13:2433–2445

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  16. Buckstein M, Rhome R, Ru M, Moshier E (2017) Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus 31(5):dox148

  17. Anap Y, Tanawade P, Mathankar M, Mane-Patil A, Bagul K, Pawar R et al (2020) Preoperative chemoradiation in locally-advanced resectable carcinoma of the esophagus in a single rural cancer hospital in Western India. South Asian J Cancer 09(03):158–162

    Article  Google Scholar 

  18. Krishnamurthy A, Mohanraj N, Radhakrishnan V, John A, Selvaluxmy G (2017) Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: a single-center experience from India with a brief review of the literature. Indian J Cancer 54(4):646

    Article  PubMed  Google Scholar 

  19. Bhattacharyya T, Arunsingh M, Chakraborty S, Harilal V, Sasidharan R, Saha S et al (2021) Can the CROSS protocol be safely implemented in real world scenario with broader eligibility criteria? Experience from a tertiary care centre in India. Ecancermedicalscience 15:1291.

  20. Lin J, Hsu C, Yeh H, Chuang C, Lin C (2018) The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus. J Chin Med Assoc 81(1):18–24

    Article  PubMed  Google Scholar 

  21. Huang R, Chao Y, Wen Y, Chang H, Tseng C, Chan S et al (2014) Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Onc 12(1). https://doi.org/10.1186/1477-7819-12-170

  22. Li C, Lin J, Yeh H, Chuang C, Chen C. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci Rep 11(1):11626. https://doi.org/10.1038/s41598-021-90753-y

  23. DeCesaris C, Berger M, Choi J, Carr S, Burrows W, Regine W et al (2020) Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointestinal Oncol 11(4):663–673

    Article  Google Scholar 

  24. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG et al (2015) A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer [Internet]. U.S. National Library of Medicine. [cited 2023 Oct 5] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294819/

  25. Fang P, Musall B, Son J, Moreno A, Hobbs B, Carter B et al (2018) Multimodal imaging of pathologic response to chemoradiation in esophageal cancer. Int J Radiat Oncol *Biology*Phys 102(4):996–1001

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, 380016, India

    Mohamed Taher Mithi, Mohit Sharma, Ketul Puj, Prandweep Hazarika, Shashank J. Pandya & Shivang Shukla

  2. Department of Pathology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, 380016, India

    Jahnavi Gandhi

  3. Department of Radiotherapy, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, 380016, India

    Ankita Parikh

Authors
  1. Mohamed Taher Mithi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ketul Puj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prandweep Hazarika
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shashank J. Pandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jahnavi Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ankita Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shivang Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ketul Puj.

Ethics declarations

Consent

Written informed consent was obtained from all patients regarding publishing data.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Mohamed Taher Mithi is the principal (first) author.

Mohit Sharma is the second author.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mithi, M.T., Sharma, M., Puj, K. et al. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Squamous Cell Carcinoma Esophagus: Demographics and Evaluation of Prognostic Factors at a Tertiary Care Center in India. Indian J Surg Oncol 15, 129–135 (2024). https://doi.org/10.1007/s13193-023-01828-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-023-01828-3

Keywords

Search

Navigation